DTA

• Description :

  DTA (2,4-Disulfamyl-5-trifluoromethylaniline) is a cyclic AMP phosphodiesterase inhibitor that binds to erythrocyte carbonic anhydrase[1][2].

• Product Name Alternative :

  2,4-Disulfamyl-5-trifluoromethylaniline

• UNSPSC :

  12352005

• Hazard Statement :

  H315, H319, H335

• Target :

  Phosphodiesterase (PDE)

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease

• Applications :

  Metabolism-protein/nucleotide metabolism

• Field of Research :

  Others

• Assay Protocol :

  https://www.medchemexpress.com/dta.html

• Purity :

  99.98

• Solubility :

  10 mM in DMSO

• Smiles :

  FC(F)(F)C1=CC(N)=C(S(N)(=O)=O)C=C1S(N)(=O)=O

• Molecular Formula :

  C7H8F3N3O4S2

• Molecular Weight :

  319.28

• Precautions :

  H315, H319, H335

• References & Citations :

  [1]Brørs O, et al. Pharmacokinetics of hydroflumethiazide during repeated oral administration to healthy subjects. Eur J Clin Pharmacol. 1979 May 21;15 (4) :281-6. |[2]Brørs O, et al. Interaction of hydroflumethiazide and 2,4-disulfamyl-5-trifluoromethylaniline with cyclic AMP phosphodiesterase and carbonic anhydrase. Acta Pharmacol Toxicol (Copenh) . 1982 Oct;51 (4) :273-7.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 2

• CAS Number :

  [654-62-6]